Covered recipient · General Payments record
MARINA C GARASSINO
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$92,270.62
67 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $71,914.75 | 24 |
| Travel and Lodging | $14,163.66 | 15 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,480.00 | 1 |
| Food and Beverage | $1,712.21 | 27 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme LLC | $41,786.55 | 25 |
| Regeneron Pharmaceuticals, Inc. | $13,716.10 | 12 |
| AstraZeneca UK Limited | $10,519.73 | 4 |
| ABBVIE INC. | $8,800.11 | 7 |
| AstraZeneca Pharmaceuticals LP | $7,892.66 | 9 |
| Daiichi Sankyo Inc. | $3,125.00 | 2 |
| Gilead Sciences, Inc. | $2,972.54 | 3 |
| E.R. Squibb & Sons, L.L.C. | $2,450.00 | 1 |
| Bayer Healthcare Pharmaceuticals Inc. | $700.00 | 1 |
| JAZZ PHARMACEUTICALS INC. | $123.42 | 1 |
| Genentech USA, Inc. | $109.68 | 1 |
| PFIZER INC. | $74.83 | 1 |
Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARINA C GARASSINO
NPI 1053999599 · CMS profile ID 9736255
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
CHICAGO, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1053999599?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARINA C GARASSINO, NPI 1053999599, CMS profile ID 9736255. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053999599?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). MARINA C GARASSINO, NPI 1053999599, CMS profile ID 9736255. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053999599?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- MARINA C GARASSINO, NPI 1053999599, CMS profile ID 9736255, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1053999599?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
67 matching records · $92,270.62 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–67 of 67.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $14.02 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234577325 | CMS |
| Merck Sharp & Dohme LLC | $27.24 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238001632 | CMS |
| Merck Sharp & Dohme LLC | $47.14 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238002646 | CMS |
| Merck Sharp & Dohme LLC | $36.67 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238033702 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,280.00 | 03/13/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206307277 | CMS |
| Regeneron Pharmaceuticals, Inc. | $416.97 | 03/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237993 | CMS |
| Regeneron Pharmaceuticals, Inc. | $73.17 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237995 | CMS |
| Regeneron Pharmaceuticals, Inc. | $94.45 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237997 | CMS |
| Regeneron Pharmaceuticals, Inc. | $33.03 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237999 | CMS |
| Regeneron Pharmaceuticals, Inc. | $83.69 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213238001 | CMS |
| Regeneron Pharmaceuticals, Inc. | $172.90 | 03/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237991 | CMS |
| Regeneron Pharmaceuticals, Inc. | $175.90 | 02/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237989 | CMS |
| AstraZeneca Pharmaceuticals LP | $134.58 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206806493 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $700.00 | 02/04/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225545389 | CMS |
| Genentech USA, Inc. | $109.68 | 02/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211542253 | CMS |
| Regeneron Pharmaceuticals, Inc. | $35.25 | 01/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237985 | CMS |
| Regeneron Pharmaceuticals, Inc. | $705.99 | 01/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237987 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,008.10 | 9 |
| PY2025 | Principal investigator | $125,123.19 | 11 |
| PY2024 | Recipient | $2,486.84 | 4 |
| PY2024 | Principal investigator | $168,290.43 | 8 |
| PY2023 | Principal investigator | $278,638.38 | 15 |
| PY2022 | Recipient | $2,030.57 | 4 |
| PY2022 | Principal investigator | $37,167.00 | 2 |
| PY2021 | Recipient | $2,159.65 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
20 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | Regeneron Pharmaceuticals, Inc. | $21.08 | 11/08/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184117631 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $95.37 | 11/08/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184117633 |
| Principal investigator 1 | Eli Lilly and Company | $499.84 | 10/27/2025 | Non-covered Recipient Entity UNIVERSITY OF CHICAGO | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187893554 |
| Principal investigator 1 | ABBVIE INC. | $13,728.00 | 09/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202509862 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $33,210.24 | 08/31/2025 | Non-covered Recipient Entity University of Chicago Medical Center | A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrolizumab with or without maintenance MK 2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1232924374 |
| Principal investigator 1 | ABBVIE INC. | $15,210.00 | 08/06/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202503421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,720.00 | 08/04/2025 | Non-covered Recipient Entity University Of Chicago | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1223386351 |
| Principal investigator 1 | AstraZeneca UK Limited | $5,720.00 | 07/30/2025 | Non-covered Recipient Entity UNIV OF CHICAGO | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) | No dispute reported | 06/30/2026 | 1185537173 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $9,555.00 | 07/03/2025 | Non-covered Recipient Entity The University Of Chicago Kovler Diabetes Center | A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio | No dispute reported | 06/30/2026 | 1236530511 |
| Principal investigator 1 | ABBVIE INC. | $3,900.00 | 07/02/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202494339 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $141.14 | 04/14/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184117629 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $139.68 | 04/09/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184117627 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $84.84 | 04/03/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184117625 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $141.69 | 03/28/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184117623 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $24.24 | 03/18/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184117621 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $327.49 | 03/07/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184117619 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $32.57 | 01/30/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184117617 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,533.06 | 01/29/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO MEDICINE | A Phase I II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti-TIGIT Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1185537175 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $28,036.45 | 01/15/2025 | Non-covered Recipient Entity The University Of Chicago Kovler Diabetes Center | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236530515 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10.60 | 01/09/2025 | Non-covered Recipient Entity UNIVERSITY OF CHICAGO | A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab with or without Carboplatinin Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04) | No dispute reported | 06/30/2026 | 1185537171 |